Gracell Biotechnologies Inc.

Company Profile

Gracell Biotechnologies Inc. had its IPO on 2021-01-08 under the ticker symbol GRCL.

The company operates in the Healthcare sector and Biotechnology industry. Gracell Biotechnologies Inc. has a staff strength of 314 employees.

Stock update

Shares of Gracell Biotechnologies Inc. opened at $3.29 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $3.09 - $3.31, and closed at $3.1.

This is a -6.06% slip from the previous day's closing price.

A total volume of 122,272 shares were traded at the close of the day’s session.

In the last one week, shares of Gracell Biotechnologies Inc. have slipped by -11.93%.

Gracell Biotechnologies Inc.'s Key Ratios

Gracell Biotechnologies Inc. has a market cap of $239.14 million, indicating a price to book ratio of 0.7919 and a price to sales ratio of 732.2116.

In the last 12-months Gracell Biotechnologies Inc.’s revenue was $0 with a gross profit of $366000 and an EBITDA of $-576316032. The EBITDA ratio measures Gracell Biotechnologies Inc.'s overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Gracell Biotechnologies Inc.’s operating margin was 0% while its return on assets stood at -23.91% with a return of equity of -43.72%.

In Q2, Gracell Biotechnologies Inc.’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Gracell Biotechnologies Inc.’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-1.28 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Gracell Biotechnologies Inc.’s profitability.

Gracell Biotechnologies Inc. stock is trading at a EV to sales ratio of 150.0357 and a EV to EBITDA ratio of 0.0518. Its price to sales ratio in the trailing 12-months stood at 732.2116.

Gracell Biotechnologies Inc. stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$1.38 billion

Total Liabilities

$193.82 million

Operating Cash Flow

$0

Capital Expenditure

$0

Dividend Payout Ratio

0%

Gracell Biotechnologies Inc. ended 2024 with $1.38 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $1.38 billion while shareholder equity stood at $1.14 billion.

Gracell Biotechnologies Inc. ended 2024 with $0 in deferred long-term liabilities, $193.82 million in other current liabilities, 225000.00 in common stock, $-1923943000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $-157976000.00 and cash and short-term investments were $1.19 billion. The company’s total short-term debt was $115,476,000 while long-term debt stood at $39.96 million.

Gracell Biotechnologies Inc.’s total current assets stands at $1.25 billion while long-term investments were $0 and short-term investments were $3.57 million. Its net receivables were $0 compared to accounts payable of $0 and inventory worth $0.

In 2024, Gracell Biotechnologies Inc.'s operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Gracell Biotechnologies Inc. paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$3.1

52-Week High

$6.99

52-Week Low

$1.4

Analyst Target Price

$12.86

Gracell Biotechnologies Inc. stock is currently trading at $3.1 per share. It touched a 52-week high of $6.99 and a 52-week low of $6.99. Analysts tracking the stock have a 12-month average target price of $12.86.

Its 50-day moving average was $3.81 and 200-day moving average was $2.81 The short ratio stood at 4.68 indicating a short percent outstanding of 0%.

Around 2341.2% of the company’s stock are held by insiders while 5289.7% are held by institutions.